

DAFTAR PUSTAKA

- Agustin, O.A. and Fitrianingsih, F. (2021) 'Kajian Interaksi Obat Berdasarkan Kategori Signifikansi Klinis Terhadap Pola Peresepan Pasien Rawat Jalan Di Apotek X Jambi', *Electronic Journal Scientific of Environmental Health And Disease*, 1(1), pp. 1–10. Available at: <https://doi.org/10.22437/esehad.v1i1.10759>.
- Akbari, P. and Khorasani-Zadeh, A. (2023) *Thiazide Diuretics*, *StatPearls*. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/30251403>.
- Anggriani, A. *et al.* (2021) 'Potensi Interaksi Obat Amlodipin the Interaction Potency of Amlodipine Hypertension Patients in a Public Health', *Jurnal Riset Kefarmasian Indoneisa*, 3(1), pp. 1–9. Available at: <https://doi.org/10.33759/jrki.v1i1.108>.
- Boamah, D., Bastian, L. and Wilcock, M. (2023) 'Evaluation of simvastatin and CYP3A4-inhibitor interactions in an inpatient population', *International Journal of Pharmacy Practice*, 31(Supplement_2), pp. ii9–ii10. Available at: <https://doi.org/10.1093/ijpp/riad074.011>.
- Cernes, R., Mashavi, M. and Zimlichman, R. (2011) 'Differential clinical profile of candesartan compared to other angiotensin receptor blockers.', *Vascular health and risk management*, 7, pp. 749–59. Available at: <https://doi.org/10.2147/VHRM.S22591>.
- Dasopang, E.S., Harahap, U. and Lindarto, D. (2015) 'Polipharmacy and Drug Interactions in Elderly Patients with Metabolic Diseases', *Indonesian Journal of Clinical Pharmacy*, 4(4), pp. 235–241. Available at: <https://doi.org/10.15416/ijcp.2015.4.4.235>.
- Defronzo, R.A. and Thier, S.O. (1980) *Pathophysiologic Approach to Hyponatremia*, *Archives of Internal Medicine*. Available at: <https://doi.org/10.1001/archinte.1980.00040020897004>.
- Drug.com (2023) *About Us*, *drug.com*. Available at: <https://www.drugs.com/support/about.html>.
- Drugbank.com (2023) *DRUGBANK ONLINE*, *drugbank.com*. Available at: <https://go.drugbank.com/about>.
- Elalem, E.G. *et al.* (2022) 'Association of cytochromes P450 3A4*22 and 3A5*3 genotypes and polymorphism with response to simvastatin in

- hypercholesterolemia patients', *PLoS ONE*, 17(7 July), pp. 1–13. Available at: <https://doi.org/10.1371/journal.pone.0260824>.
- Eliani Tirta, P.M.A., Empuadji, P.P. and Setiawan, P.Y.B. (2023) 'Kajian Retrospektif Potensi Interaksi Obat Hipertensi Pada Peresepan Pasien Poli Penyakit Dalam Di Rumah Sakit Swasta X Di Denpasar', *Jurnal Riset Kesehatan Nasional*, 7(2), pp. 98–103. Available at: <https://doi.org/10.37294/jrkn.v7i2.501>.
- Farzam, K. and Jan, A. (2023) *Beta Blockers*, *StatPearls*. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/30227820>.
- Ganet-Schoeller, M. and Ducamp, M. (2010) *LPV control for flexible launcher, AIAA Guidance, Navigation, and Control Conference*. Available at: <https://doi.org/10.2514/6.2010-8193>.
- Grace, B.Y. and Nov, W. (2023) 'Indonesia Drug Registration Process | ChemLinked', pp. 1–7. Available at: <https://baipharm.chemlinked.com/insights/indonesia-drug-registration-pathway>.
- Hanutami, B. and Dandan, K.L. (2019) 'Identifikasi potensi interaksi antar obat pada resep umum di Apotek Kimia Farma 58 Kota Bandung bulan April 2019', *Farmaka*, 17(2), pp. 57–64.
- Joint, G. and Committee, N. (2016) 'JNC 8: Evidence-based Guideline Penanganan Pasien Hipertensi Dewasa', 43(1), pp. 54–59.
- Jones, K.E. *et al.* (2024) 'The Evolving Role of Calcium Channel Blockers in Hypertension Management : Pharmacological and Clinical Considerations', pp. 6315–6327.
- Kandarini, Y. (2017) 'Tatalaksana Farmakologi Terapi Hipertensi', *Divisi Ginjal dan Hipertensi RSUP Sanglah Denpasar*, pp. 13–14.
- Khairiyah, U., Yuswar, M.A. and Purwanti, N.U. (2022) 'Pola Penggunaan Obat Antihipertensi Pada Pasien Hipertensi di Instalasi Rawat Jalan Rumah Sakit', *Jurnal Syifa Sciences and Clinical Reasearch (JSSCR)*, 4(3), pp. 609–617.
- Khusna N, Murdiana, H. (2021) 'Identifikasi Drug Related Problems (DRPs) Obat Antihipertensi pada Pasien Hipertensi di Peskesmas Dharma Rini Temanggung', *Jurnal Farmasi Dan Kesehatan Indonesia*, I(2), pp. 13–26.

- Lee, E.M. (2023) 'Calcium channel blockers for hypertension: old, but still useful', *Cardiovascular Prevention and Pharmacotherapy*, 5(4), pp. 113–125. Available at: <https://doi.org/10.36011/cpp.2023.5.e16>.
- Lukito, A.A. (2023) 'Panduan Promotif Dan Preventif Hipertensi 2023', pp. 1–88.
- Maggioni, A.P. (2006) 'Efficacy of Angiotensin receptor blockers in cardiovascular disease.', *Cardiovascular drugs and therapy*, 20(4), pp. 295–308. Available at: <https://doi.org/10.1007/s10557-006-9799-9>.
- Maggioni, A.P. and Latini, R. (2002) 'The angiotensin-receptor blockers: from antihypertensives to cardiovascular all-round medications in 10 years?', *Blood pressure*, 11(6), pp. 328–38. Available at: <https://doi.org/10.1080/080370502321095285>.
- Malacco, E. *et al.* (2004) 'Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study.', *Clinical therapeutics*, 26(6), pp. 855–65. Available at: [https://doi.org/10.1016/s0149-2918\(04\)90129-4](https://doi.org/10.1016/s0149-2918(04)90129-4).
- Mariam, S., Salsabilila Y, A. and Kurniasih, N. (2022) 'Evaluasi Kejadian Interaksi Obat Antihipertensi Pada Pasien Rawat Jalan Di Puskesmas Tanah Sareal', *Jurnal Farmamedika (Pharmamedica Journal)*, 7(2), pp. 157–164. Available at: <https://doi.org/10.47219/ath.v7i2.189>.
- Masputra, M.H.C., Setiyono, J. and Irawati, I. (2020) 'Keadilan Terhadap Dokter Pada Kasus Penggunaan Obat Yang Belum Terdaftar Di Bpom Republik Indonesia', *Jurnal Pembangunan Hukum Indonesia*, 2(1), pp. 102–116. Available at: <https://doi.org/10.14710/jphi.v2i1.102-116>.
- McKeever, R.G. and Hamilton, R.J. (2023) *Calcium Channel Blockers*, *StatPearls*. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/30737550>.
- Medscape (no date) *No Title*. Available at: <https://reference.medscape.com/drug-interactionchecker>.
- PERHI, K. (2021) 'KONSENSUS PENATALAKSANAAN HIPERTENSI 2021: Update Konsensus PERHI 2019', *I-Hefcard.Com*, p. 118. Available at: http://www.inash.or.id/upload/event/event_Update_konsensus_2019123191.pdf.

- Rantisari, A.M.D. *et al.* (2021) 'Volume 3 Nomor 2 Bulan Juni 2021 Hal . 33-40 Evaluasi Interaksi Obat pada Pasien Hipertensi di Rumah Sakit Umum Daerah Labuang Baji Makassar', *Journal of Healt, Economics, Sains and Technology (J-HEST)*, 3(2), pp. 33–40.
- Robby, R. *et al.* (2022) 'POTENSI INTERAKSI OBAT ANTIHIPERTENSI PADA PASIEN GERIATRI RAWAT INAP DI SALAH SATU RUMAH SAKIT KOTA BANDUNG', *Pharmacoscript*, 5(1), pp. 71–91. Available at: <https://doi.org/10.36423/pharmacoscript.v5i1.890>.
- Rumi, A., Aulia, R. and Tandah, M.R. (2023) 'Identifikasi Kejadian Adverse Drug Reactions pada Penggunaan Amlodipin di Instalasi Rawat Jalan RSUD Undata', *Majalah Farmaseutik*, 19(3), pp. 409–416.
- Susanti, R. *et al.* (2023) 'Kajian Interaksi Obat Antihipertensi pada Pasien Rawat Jalan di Klinik "X" Kabupaten Garut', *Jurnal Ilmu Farmasi dan Farmasi Klinik*, 20(1), p. 37. Available at: <https://doi.org/10.31942/jiffk.v20i1.7515>.
- Weber, M.A. (2002) 'The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease.', *Reviews in cardiovascular medicine*, 3(4), pp. 183–91. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12556752>.
- Yulanda, G. (2017) 'Penatalaksanaan Hipertensi Primer', *Jurnal Majority*, 6(1), pp. 25–33.
- Zhao, X. *et al.* (2021) 'Severe secondary hyperkalemia and arrhythmia from drug interactions between calcium-channel blocker and voriconazole: a case presentation', *BMC Nephrology*, 22(1), pp. 6–11. Available at: <https://doi.org/10.1186/s12882-021-02370-6>.